Post-progression survival has a greater influence on the OS of patients with NSCLC harboring secondary T790M mutation when osimertinib is administered as a second-line therapy, in addition to first-line treatment with first- or second-generation EGFR-TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.